An eagerly awaited result presented by Tony Mok CUHK Medicine on CheckMate 722 in #esmoasia22 . A negative study and even if the sample size is large enough to meet statistical significance, the 2 week PFS difference is not impressive.
I am honored to present the result of the Asian sup-group of RATIONALE-306 study, which compared chemotherapy vs. chemo plus tislelizumab for 1st line chemo of ESCC. #ESMOAsia22 #Esophageal
Congratulations to Dr Karine Azar from CHU Notre Dame des Secours presenting a poster during poster session at #ESMOAsia22
Poster with updated results from ADAURA study A/Prof Tom John also a succinct mini oral presentation yesterday by Tom. ILD rate still around 3% and would need some soul searching on how this would take on for patients as they embark on an adjuvant 3 year drug journey. #ESMOAsia22
Our fearless leader Dr Deme Karikios representing Medical Oncology Group of Australia at #ESMOAsia22 #🇦🇺
Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1 . Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22
Nice lecture in the morning by #johnhannen & #laviniaspain on irAE with interesting data on IO rechallenge and toci prophylaxis and Rashid Lui 雷諾信 discussion on ir-colitis #ESMOAsia22
#ESMOAsia22 Opening cerimony! Happy to be here in person this year! Important meeting to discuss the disparities in cancer patient care and for networking!
Congratulations, #ESMOAsia22 for a successful F2F conference! Glad to have met a lot of colleagues and learned from the experts in the field of Oncology. 😊